Targeted metabolomics is a method that involves the quantification of a predefined set of metabolites. It is a valuable tool for the identification of biomarkers for diseases and drug response. Recent advances in targeted metabolomics include the use of multiplexed assays and microfluidics-based platforms for high-throughput analysis.
Untargeted metabolomics involves the analysis of all detectable metabolites in a biological sample. It is a powerful approach for the discovery of novel biomarkers and pathways. Recent advances in untargeted metabolomics include the development of new data analysis tools such as machine learning algorithms and network analysis.
Metabolic phenotyping is the systematic analysis of the metabolome in a population. It is used to identify metabolic subtypes that can aid in disease diagnosis and personalized medicine. Recent advances in metabolic phenotyping include the use of non-invasive sampling methods such as breath analysis and the integration of multi-omics data.
Pharmacometabolomics is the study of the relationship between drug response and metabolites. It has the potential to improve drug discovery and personalized medicine by identifying biomarkers of drug response and toxicity. Recent advances in pharmacometabolomics include the use of multi-omics data integration and the development of predictive models for drug response.
Single-cell metabolomics involves the analysis of metabolites in individual cells. It is a valuable tool for the study of cellular heterogeneity and metabolic pathways. Recent advances in single-cell metabolomics include the development of microfluidic devices for high-throughput analysis and the integration of single-cell transcriptomics and proteomics data.
In conclusion, metabolomics and pharmacometabolomics are rapidly evolving fields with significant potential for drug discovery, personalized medicine, and disease diagnosis. Recent advances in targeted and untargeted metabolomics, metabolic phenotyping, pharmacometabolomics, and single-cell metabolomics are opening up new avenues for research and development.